Jun Li

This inventor holds 73 USPTO granted patents and 7 published patent applications and 32 EPO patents, primarily in LPA Antagonists (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Thomson Licensing, Syngene International Limited. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jun Li. Retrieved from https://idiyas.com/inventor/jun-li-rwzqiq6v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 73 (Patent Applications = 7)

% Patents Active = 71.2

EPO Patents = 32 (Patent Applications = 17)

Average Co-Inventor Count = 4.5

ph-index = 13

Forward Citations = 762(Granted Patents)

Forward Citations (Not Self Cited) = 700(Dec 10, 2025)

Inventors with similar research interests:

Location History:

North Brunswick, NJ (US) (2002)
Indianapolis, IN (US) (2011 - 2014)
Plainsboro, NJ (US) (2006 - 2015)
Cranberry, NJ (US) (2017)
Princeton, NJ (US) (2003 - 2020)
Langhorne, PA (US) (2006 - 2021)
Pittsburgh, PA (US) (2021 - 2023)

Company Filing History:

43 out of 3,742

Bristol-Myers Squibb Compnay

Syngene International Limited

patents

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

LPA Antagonists

Triazole Compounds

Isoxazole Compounds

Pyrazole Acids

Heteroaryl Modulators

Wireless Networks

Media Access Control

Dynamic Scheduling

73 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565487 - Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (2026-03-03),

2. 12435057 - Triazole carboxylic acids as LPA antagonists (2025-10-07),

3. 12384768 - Isoxazole carboxylic acids as LPA antagonists (2025-08-12),

4. 12195444 - Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists (2025-01-14),

5. 11697646 - Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists (2023-07-11),

6. RE49352 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2023-01-02),

7. 11352345 - Cyclohexyl acid pyrazole azoles as LPA antagonists (2022-06-07),

8. 11319315 - Cyclohexyl acid triazole azoles as LPA antagonists (2022-05-03),

9. 11312706 - Cyclohexyl acid pyrazole azines as LPA antagonists (2022-04-26),

10. 11267800 - Cyclohexyl acid triazole azines as LPA antagonists (2022-03-08),

11. 11261174 - Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists (2022-03-01),

12. 11180488 - Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists (2021-11-23),

13. 11008300 - Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists (2021-05-18),

14. 11007180 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2021-05-18),

15. 10899745 - Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (2021-01-26),

Title: Inventor Jun Li - Pioneering Innovations in Princeton

Introduction: Jun Li is a distinguished inventor based in Princeton, NJ, known for his groundbreaking contributions to various technological fields.

Latest Patents: Jun Li holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and ingenuity in inventing cutting-edge solutions.

Career Highlights: With a career spanning over two decades, Jun Li has worked for renowned tech companies and research institutions, leading teams to develop innovative products and technologies that have revolutionized their respective industries.

Collaborations: Jun Li has collaborated with top scientists, engineers, and researchers worldwide, fostering a culture of innovation and knowledge-sharing to drive progress and create impactful inventions.

Conclusion: Jun Li's passion for innovation, coupled with his relentless pursuit of excellence, continues to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.